Brief: Gracell Biotechnologies Doses First Patient In Phase 2 Portion Of Registrational Phase 1/2 Clinical Trial Evaluating Gc007g
17/10/2022 14:03
Oct 17 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES DOSES FIRST PATIENT IN PHASE 2
PORTION
OF REGISTRATIONAL PHASE 1/2 CLINICAL TRIAL EVALUATING GC007G FOR
TREATMENT OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
* GRACELL BIOTECHNOLOGIES INC- DATA FROM PHASE 1 TRIAL
SHOWED
ENCOURAGING EFFICACY AND A FAVORABLE SAFETY PROFILE
Source text for Eikon: ID:nPn23HmnMa
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27